Albumin Administration After Large‑Volume Paracentesis

Pathophysiology of Post‑Paracentesis Circulatory Dysfunction (PPCD)

Removal of > 5 L of ascitic fluid markedly reduces effective blood volume, triggering activation of vasoconstrictor systems (renin‑angiotensin‑aldosterone system and sympathetic nervous system) to preserve circulatory homeostasis【1】【3】.
Approximately 20 % of patients develop hepatorenal syndrome or dilutional hyponatraemia after large‑volume removal【1】.
Vasoconstriction increases intra‑hepatic resistance, raising portal pressure【1】【4】.
Circulatory dysfunction leads to rapid re‑accumulation of ascites and is independently associated with shortened survival【1】【4】.

Albumin is the most effective plasma expander for preventing PPCD when > 5 L of ascites are removed【1】【4】【2】.
Meta‑analysis (high‑quality evidence) shows albumin reduces the odds of PPCD by 61 % (OR 0.39, 95 % CI 0.27‑0.55)【3】【5】.
The same meta‑analysis demonstrates a 42 % reduction in hyponatraemia risk (OR 0.58, 95 % CI 0.39‑0.87)【3】【5】.
Mortality is lowered by 36 % with albumin compared with alternative plasma expanders (OR 0.64, 95 % CI 0.41‑0.98)【3】【5】.
For volumes < 5 L, dextran‑70 or polygeline provide comparable efficacy, but albumin becomes definitively superior when > 5 L are removed【1】【4】【6】.

Standard dosing is 6–8 g of albumin per litre of ascitic fluid removed【7】【8】【9】【2】【10】.
- Example: a 5‑L paracentesis requires ≈30–40 g of albumin【10】.
- Example: an 8‑L paracentesis requires ≈48–64 g of albumin【10】.
Albumin should be infused slowly at the end of the procedure to avoid cardiac overload in patients with latent cirrhotic cardiomyopathy【1】【4】【5】.

The risk of PPCD rises with the volume removed, especially when > 8 L are extracted in a single session【5】【10】.
When feasible, limit a single‑session paracentesis to < 8 L to mitigate PPCD risk【5】.
In high‑risk patients (e.g., hypotension, renal insufficiency, electrolyte abnormalities), consider albumin even for < 5 L removals【9】.

Alternative plasma expanders are not recommended for large‑volume paracentesis > 5 L because of inferior efficacy【2】【6】【11】.
Starch‑based expanders carry concerns for renal failure and hepatic accumulation【1】【4】【11】.
Polygeline is associated with prion‑transmission risk and has been discontinued in many countries【1】【4】.

Although albumin has higher upfront costs, it is more cost‑effective than cheaper alternatives by reducing liver‑related complications within 30 days post‑procedure【1】【2】【11】.